eNews June 10, 2020

The latest news affecting you and your customers… from the Independent Medical Specialty Dealers Association

How is COVID-19 affecting your business, your people, your customers? IMDA is a membership organization, and in times like these, we can all use some camaraderie. If you have a COVID story to share, advice to offer, or a warning to sound, send it to Mark Thill, IMDA’s communications director, at mdthill1913@gmail.com, with the subject line “IMDA COVID story.” We’ll compile them and send them back out to you.


What to expect on upcoming sales calls

CMS’s recommendations for hospitals caring for COVID-19 and non-COVID-19 patients will affect sales reps. Among them: 
  • For in-hospital care and procedures, to the extent feasible, designate space specifically for COVID-19 Care or non-COVID-19 care through the use of strategies such as separate floors or dedicated space (e.g., separate operating rooms, radiology suites, procedure labs). Avoid crossover of patients, staff, supplies, and personnel as feasible.
  • Within the facility, administrative and engineering controls should be established to facilitate social distancing, such as minimizing time in waiting areas, spacing chairs, and maintaining low patient volumes. 
  • The number of visitors should be minimized. Actively assess all visitors for COVID-19 symptoms upon entry to the facility. If COVID-19 symptoms are present, the visitor should not be allowed entry into the facility and should be referred for care as appropriate. 


Medicare grants quick turnaround on payment

decisions for innovative technologies

It’s been about six months since the Centers for Medicare & Medicaid Services launched its Transitional Pass-Through (TPT) payment category, intended to give Medicare beneficiaries quick access to innovative outpatient technologies soon after those technologies are cleared by the U.S. Food and Drug Administration. On June 8, Boston Scientific announced that CMS had approved its application for a TPT for its single-use endoscopes, including the EXALT™ Model D Single-Use Duodenoscope, which received FDA clearance in December 2019.

Remote patient monitoring options 

expanded during COVID-19

FDA is allowing manufacturers to modify certain non-invasive remote patient-monitoring devices for the duration of the COVID-19 public health emergency. The FDA says that such modifications “will help eliminate unnecessary patient contact and ease the burden on hospitals, other healthcare facilities and healthcare professionals that are experiencing increased demand due to the COVID-19 pandemic.” Among the acceptable modifications: Devices previously marketed only for use in hospitals or other healthcare facilities can be now be used in the home setting.